NL1016435C1 - Kristallijne base van Citalopram. - Google Patents
Kristallijne base van Citalopram. Download PDFInfo
- Publication number
- NL1016435C1 NL1016435C1 NL1016435A NL1016435A NL1016435C1 NL 1016435 C1 NL1016435 C1 NL 1016435C1 NL 1016435 A NL1016435 A NL 1016435A NL 1016435 A NL1016435 A NL 1016435A NL 1016435 C1 NL1016435 C1 NL 1016435C1
- Authority
- NL
- Netherlands
- Prior art keywords
- citalopram
- base
- salt
- hydrobromide
- hydrochloride
- Prior art date
Links
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 title claims description 66
- 229960001653 citalopram Drugs 0.000 title claims description 66
- 239000002585 base Substances 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000012458 free base Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 claims 1
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 claims 1
- XAJMJYPAJNLKIS-UHFFFAOYSA-N [5-(4-bromophenyl)furan-2-yl]methanamine Chemical compound O1C(CN)=CC=C1C1=CC=C(Br)C=C1 XAJMJYPAJNLKIS-UHFFFAOYSA-N 0.000 claims 1
- 229960000584 citalopram hydrobromide Drugs 0.000 claims 1
- 239000012045 crude solution Substances 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 239000003826 tablet Substances 0.000 description 28
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 5
- -1 5-thiazolinyl group Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Laminated Bodies (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK200000402 | 2000-03-13 | ||
DKPA200000402 | 2000-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
NL1016435C1 true NL1016435C1 (nl) | 2000-11-06 |
Family
ID=8159320
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL1016435A NL1016435C1 (nl) | 2000-03-13 | 2000-10-18 | Kristallijne base van Citalopram. |
NL1017413A NL1017413C1 (nl) | 2000-03-13 | 2001-02-21 | Kristallijne base van Citalopram. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL1017413A NL1017413C1 (nl) | 2000-03-13 | 2001-02-21 | Kristallijne base van Citalopram. |
Country Status (42)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1462447A3 (en) * | 2000-12-22 | 2004-11-17 | H. Lundbeck A/S | Method for the preparation of pure citalopram |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1173431B2 (en) | 1999-04-14 | 2009-08-26 | H. Lundbeck A/S | Method for the preparation of citalopram |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
US6299622B1 (en) | 1999-08-19 | 2001-10-09 | Fox Hollow Technologies, Inc. | Atherectomy catheter with aligned imager |
US7708749B2 (en) | 2000-12-20 | 2010-05-04 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US7713279B2 (en) | 2000-12-20 | 2010-05-11 | Fox Hollow Technologies, Inc. | Method and devices for cutting tissue |
US7887556B2 (en) | 2000-12-20 | 2011-02-15 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US8328829B2 (en) | 1999-08-19 | 2012-12-11 | Covidien Lp | High capacity debulking catheter with razor edge cutting window |
NL1017417C1 (nl) | 2000-03-03 | 2001-03-16 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
IES20010206A2 (en) | 2000-03-13 | 2002-03-06 | Lundbeck & Co As H | Method for the preparation of citalopram |
GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
AR032455A1 (es) | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva |
IS6021A (is) * | 2000-08-10 | 2001-10-20 | H. Lundbeck A/S | Lyfjasamsetningar sem innihalda sítalópram |
GB2376233B (en) * | 2000-08-10 | 2003-09-10 | Lundbeck & Co As H | Crystals of a pharmaceutically acceptable salt of citalopram wherein the median size of the crystals is at least 40 microns |
ATE499054T1 (de) | 2000-12-20 | 2011-03-15 | Fox Hollow Technologies Inc | Verkleinerungskatheter |
AU2001100195B4 (en) * | 2001-01-05 | 2001-12-20 | H Lundbeck As | Pharmaceutical composition containing citalopram. |
GB0105627D0 (en) * | 2001-03-07 | 2001-04-25 | Cipla Ltd | Preparation of phthalanes |
MXPA03008777A (es) * | 2001-05-01 | 2004-02-12 | Lundbeck & Co As H | El uso de escitalopram enantiomericamente puro. |
KR20040028947A (ko) | 2001-07-31 | 2004-04-03 | 하. 룬트벡 아크티에 셀스카브 | 에시탈로프람 함유 결정 조성물 |
WO2003057132A2 (en) * | 2002-01-07 | 2003-07-17 | Sun Pharmaceutical Industries Limited | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile |
GB0204607D0 (en) * | 2002-02-27 | 2002-04-10 | Matrix Lab Ltd | Process |
GB2387844B (en) * | 2002-02-27 | 2005-05-11 | Matrix Lab Ltd | Separation of impurities from a crude mixture of citalopram |
GB2385848A (en) * | 2002-02-27 | 2003-09-03 | Cipla Ltd | Citalopram salts |
GB2386119A (en) * | 2002-02-27 | 2003-09-10 | Cipla Ltd | Purification of citalopram |
GB2386118A (en) * | 2002-02-27 | 2003-09-10 | Cipla Ltd | Citalopram |
EP1346989A1 (en) * | 2002-03-21 | 2003-09-24 | Jubilant Organosys Limited | Improved process for the preparation of citalopram and its hydrobromide |
GB0206708D0 (en) * | 2002-03-21 | 2002-05-01 | Cipla Ltd | Pharmaceutical salts |
US6812355B2 (en) | 2002-10-22 | 2004-11-02 | Sekhsaria Chemicals Limited | Process for the manufacture of citalopram hydrobromide from 5-bromophthalide |
AU2003223105A1 (en) * | 2003-03-24 | 2004-10-18 | Hetero Drugs Limited | Novel crystalline forms of (s)-citalopram oxalate |
AU2003238676A1 (en) * | 2003-04-21 | 2004-11-19 | Podile Khadgapathi | An improved process for the preparation of citalopram hydrobromide |
US8246640B2 (en) | 2003-04-22 | 2012-08-21 | Tyco Healthcare Group Lp | Methods and devices for cutting tissue at a vascular location |
US7019153B2 (en) | 2003-06-10 | 2006-03-28 | Sun Pharmaceutical Industries Limited | Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid |
GB0317475D0 (en) * | 2003-07-25 | 2003-08-27 | Meditab Specialities Pvt Ltd | Product |
JP4025735B2 (ja) * | 2003-08-21 | 2007-12-26 | ローム アンド ハース カンパニー | 水性系を処理する方法 |
GB0320312D0 (en) | 2003-08-29 | 2003-10-01 | Novartis Ag | Purification process |
CN100569765C (zh) | 2003-12-19 | 2009-12-16 | 杭州民生药业集团有限公司 | 西酞普兰中间体晶体碱 |
ITTO20050301A1 (it) * | 2005-05-05 | 2006-11-06 | Errekappa Euroterapici Spa | Formulazioni liquide orali contenenti citalopram |
WO2006123243A2 (en) * | 2005-05-20 | 2006-11-23 | Aurobindo Pharma Limited | Pharmaceutical dosage forms comprising escitalopram in form of granules |
TWI347942B (en) * | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
WO2007002597A2 (en) | 2005-06-27 | 2007-01-04 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
US20070276419A1 (en) | 2006-05-26 | 2007-11-29 | Fox Hollow Technologies, Inc. | Methods and devices for rotating an active element and an energy emitter on a catheter |
US8784440B2 (en) | 2008-02-25 | 2014-07-22 | Covidien Lp | Methods and devices for cutting tissue |
EP2358282B1 (en) | 2008-10-13 | 2017-12-06 | Covidien LP | Devices for manipulating a catheter shaft |
ES2532407T3 (es) | 2009-04-29 | 2015-03-26 | Covidien Lp | Dispositivos para cortar y raspar tejido |
KR101323514B1 (ko) | 2009-05-14 | 2013-10-29 | 코비디엔 엘피 | 세척이 용이한 죽상반 절제 카테터 및 사용 방법 |
CA2781046C (en) | 2009-12-02 | 2014-09-16 | Tyco Healthcare Group Lp | Methods and devices for cutting tissue |
AU2010328078B2 (en) | 2009-12-11 | 2013-07-04 | Covidien Lp | Material removal device having improved material capture efficiency and methods of use |
JP5690928B2 (ja) | 2010-06-14 | 2015-03-25 | コヴィディエン リミテッド パートナーシップ | 物質除去デバイス |
JP5636114B2 (ja) | 2010-10-28 | 2014-12-03 | コヴィディエン リミテッド パートナーシップ | 物質除去デバイスおよび使用方法 |
RU2553930C2 (ru) | 2010-11-11 | 2015-06-20 | Ковидиен Лп | Гибкие фрагментирующие катетеры с визуализацией и способы их использования и изготовления |
JP5806407B2 (ja) | 2011-09-01 | 2015-11-10 | コヴィディエン リミテッド パートナーシップ | 螺旋駆動軸を有するカテーテルおよび製造方法 |
US9532844B2 (en) | 2012-09-13 | 2017-01-03 | Covidien Lp | Cleaning device for medical instrument and method of use |
US9943329B2 (en) | 2012-11-08 | 2018-04-17 | Covidien Lp | Tissue-removing catheter with rotatable cutter |
WO2015200702A1 (en) | 2014-06-27 | 2015-12-30 | Covidien Lp | Cleaning device for catheter and catheter including the same |
US10314667B2 (en) | 2015-03-25 | 2019-06-11 | Covidien Lp | Cleaning device for cleaning medical instrument |
US10292721B2 (en) | 2015-07-20 | 2019-05-21 | Covidien Lp | Tissue-removing catheter including movable distal tip |
US10314664B2 (en) | 2015-10-07 | 2019-06-11 | Covidien Lp | Tissue-removing catheter and tissue-removing element with depth stop |
US20240024288A1 (en) | 2019-07-19 | 2024-01-25 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2233970A (en) * | 1941-03-04 | Quinoline compound and process of | ||
US2584429A (en) * | 1950-12-29 | 1952-02-05 | Rohm & Haas | 1,1-diphenyl-4-tert.-amino-2-butyne-1-ols |
GB1143702A (sh) * | 1965-03-18 | |||
US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
DK213290D0 (da) | 1990-09-06 | 1990-09-06 | Lundbeck & Co As H | Treatment of cerebrovascular disorders |
CA2120874E (en) * | 1994-04-08 | 2002-01-08 | Keshava Murthy | Form of form 1 ranitidine |
HU228744B1 (en) * | 1997-07-08 | 2013-05-28 | Lundbeck & Co As H | Method for preparation of citalopram and intermediates used for them |
UA62985C2 (en) * | 1997-11-10 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
EP1042310B1 (en) * | 1997-11-11 | 2002-07-31 | H. Lundbeck A/S | Method for the preparation of citalopram |
CN1129592C (zh) | 1998-10-20 | 2003-12-03 | H·隆德贝克有限公司 | 制备西酞普兰的方法 |
EP1173431B2 (en) | 1999-04-14 | 2009-08-26 | H. Lundbeck A/S | Method for the preparation of citalopram |
ITMI991579A1 (it) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
ITMI991581A1 (it) | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
US6433196B1 (en) * | 2000-02-17 | 2002-08-13 | Sumika Fine Chemicals Co., Ltd. | Production method of citalopram, intermediate therefor and production method of the intermediate |
GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
-
2000
- 2000-04-13 GB GB0105982A patent/GB2357762B/en not_active Expired - Fee Related
- 2000-04-18 HU HU0001581A patent/HU0001581D0/hu unknown
- 2000-04-20 DE DE20007303U patent/DE20007303U1/de not_active Ceased
- 2000-10-18 NL NL1016435A patent/NL1016435C1/nl not_active IP Right Cessation
- 2000-11-09 IT IT2000MI002425A patent/IT1319645B1/it active
- 2000-12-05 US US09/730,490 patent/US20010031784A1/en not_active Abandoned
-
2001
- 2001-01-25 FI FI20010156A patent/FI20010156A0/fi unknown
- 2001-01-26 HU HU0100450A patent/HU0100450D0/hu unknown
- 2001-02-05 GB GBGB0102797.8A patent/GB0102797D0/en not_active Ceased
- 2001-02-05 DK DK200100183A patent/DK173903B1/da not_active IP Right Cessation
- 2001-02-05 IS IS5841A patent/IS5841A/is unknown
- 2001-02-05 HU HU0100531A patent/HUP0100531A3/hu unknown
- 2001-02-06 NO NO20010619A patent/NO312031B1/no active IP Right Review Request
- 2001-02-07 IE IE20010109A patent/IES20010109A2/en not_active IP Right Cessation
- 2001-02-07 FI FI20010225A patent/FI109022B/fi active
- 2001-02-12 GR GR20010100074A patent/GR1003796B/el unknown
- 2001-02-20 DE DE10108042A patent/DE10108042A1/de not_active Withdrawn
- 2001-02-20 DE DE20121240U patent/DE20121240U1/de not_active Ceased
- 2001-02-20 DE DE10164687A patent/DE10164687B4/de not_active Revoked
- 2001-02-21 NL NL1017413A patent/NL1017413C1/nl not_active IP Right Cessation
- 2001-02-21 FR FR0102340A patent/FR2806086B1/fr not_active Expired - Fee Related
- 2001-02-22 CH CH00580/01A patent/CH691537A5/de not_active IP Right Cessation
- 2001-02-22 CH CH00321/01A patent/CH691477A5/de not_active IP Right Cessation
- 2001-02-28 EP EP01909568A patent/EP1169314B2/en not_active Expired - Lifetime
- 2001-02-28 BR BR0109373-8A patent/BR0109373A/pt not_active IP Right Cessation
- 2001-02-28 PL PL36015801A patent/PL360158A1/xx not_active Application Discontinuation
- 2001-02-28 WO PCT/DK2001/000137 patent/WO2001068627A1/en active Application Filing
- 2001-02-28 DK DK02009350T patent/DK1227088T3/da active
- 2001-02-28 DE DE1227088T patent/DE1227088T1/de active Pending
- 2001-02-28 UA UA2002097314A patent/UA74360C2/uk unknown
- 2001-02-28 IL IL14733901A patent/IL147339A/en not_active IP Right Cessation
- 2001-02-28 SI SI200130001T patent/SI1169314T2/sl unknown
- 2001-02-28 JP JP2001567719A patent/JP2003527383A/ja active Pending
- 2001-02-28 IL IL15807201A patent/IL158072A0/xx unknown
- 2001-02-28 AT AT02009350T patent/ATE250050T1/de not_active IP Right Cessation
- 2001-02-28 DK DK01909568T patent/DK1169314T3/da active
- 2001-02-28 YU YU68802A patent/YU68802A/sh unknown
- 2001-02-28 PT PT02009350T patent/PT1227088E/pt unknown
- 2001-02-28 EA EA200200972A patent/EA200200972A1/ru unknown
- 2001-02-28 TR TR2002/02185T patent/TR200202185T2/xx unknown
- 2001-02-28 KR KR1020027012048A patent/KR20020080486A/ko not_active Application Discontinuation
- 2001-02-28 IT IT2001MI000406A patent/ITMI20010406A1/it unknown
- 2001-02-28 ES ES01909568T patent/ES2173054T3/es not_active Expired - Lifetime
- 2001-02-28 CA CA002360287A patent/CA2360287C/en not_active Expired - Lifetime
- 2001-02-28 SK SK1313-2002A patent/SK285528B6/sk unknown
- 2001-02-28 DE DE60100786T patent/DE60100786T2/de not_active Revoked
- 2001-02-28 EP EP02009350A patent/EP1227088B1/en not_active Revoked
- 2001-02-28 AT AT01909568T patent/ATE223396T1/de not_active IP Right Cessation
- 2001-02-28 CA CA002411732A patent/CA2411732A1/en not_active Abandoned
- 2001-02-28 CN CNB018093418A patent/CN1258530C/zh not_active Expired - Fee Related
- 2001-02-28 PT PT01909568T patent/PT1169314E/pt unknown
- 2001-02-28 MX MXPA02008793A patent/MXPA02008793A/es active IP Right Grant
- 2001-02-28 CN CNA2005100091603A patent/CN1680350A/zh active Pending
- 2001-02-28 SI SI200130031T patent/SI1227088T1/xx unknown
- 2001-02-28 ES ES02009350T patent/ES2180471T3/es not_active Expired - Lifetime
- 2001-02-28 BE BE2001/0136A patent/BE1013210A3/fr not_active IP Right Cessation
- 2001-02-28 DE DE60100022T patent/DE60100022T3/de not_active Expired - Fee Related
- 2001-02-28 AR ARP010100934A patent/AR029811A1/es unknown
- 2001-02-28 AU AU37252/01A patent/AU746664B2/en not_active Ceased
- 2001-03-05 CZ CZ2001808A patent/CZ292077B6/cs not_active IP Right Cessation
- 2001-03-07 AT AT0016601U patent/AT4364U1/de unknown
- 2001-03-09 ES ES200100548A patent/ES2159491B1/es not_active Expired - Fee Related
- 2001-07-26 AU AU2001100197A patent/AU2001100197B4/en not_active Expired
- 2001-09-14 SE SE0103046A patent/SE517136C2/sv not_active IP Right Cessation
-
2002
- 2002-01-23 NO NO20020356A patent/NO315851B1/no unknown
- 2002-03-12 SE SE0200730A patent/SE526022C2/sv not_active IP Right Cessation
- 2002-09-05 ZA ZA200207148A patent/ZA200207148B/en unknown
- 2002-09-05 BG BG107065A patent/BG107065A/bg unknown
- 2002-09-12 US US10/245,824 patent/US20030078442A1/en not_active Abandoned
- 2002-09-18 HR HRP20020756 patent/HRP20020756A2/hr not_active Application Discontinuation
-
2003
- 2003-10-02 HK HK03107120A patent/HK1054750A1/xx not_active IP Right Cessation
- 2003-12-19 US US10/741,553 patent/US20040132808A1/en not_active Abandoned
- 2003-12-30 US US10/750,049 patent/US20040167210A1/en not_active Abandoned
-
2005
- 2005-03-24 US US11/090,337 patent/US20050165244A1/en not_active Abandoned
- 2005-03-24 US US11/090,336 patent/US20050165092A1/en not_active Abandoned
-
2006
- 2006-06-20 US US11/425,321 patent/US20060247451A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1462447A3 (en) * | 2000-12-22 | 2004-11-17 | H. Lundbeck A/S | Method for the preparation of pure citalopram |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL1016435C1 (nl) | Kristallijne base van Citalopram. | |
US20060229459A1 (en) | Crystalline base of citalopram | |
US7723533B2 (en) | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base | |
AU2006261452B2 (en) | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD1N | Patents in respect of which a request for novelty search has been filed |
Free format text: MR.IR. A.W. PRINS |
|
RD1A | Patents in respect of which a request for advice has been filed [in relation to nullification] | ||
RD2N | Patents in respect of which a decision has been taken or a report has been made (novelty report) |
Effective date: 20020905 |
|
VD2 | Discontinued due to expiration of the term of protection |
Effective date: 20061018 |